Track the Akeso, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in Hong Kong. Shares are quoted on the HK market, under the supervision of HKEX. Market capitalisation: €83.1bn. The latest transaction was reported on 31 July 2026 (Purchase). Among the most active insiders: Xia Yu. The full history is accessible without an account.
10
Insider Decl.
n/a
Thresholds
€3m
10 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Akeso, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: HK$168.01.
19Σ signal
Buys €3mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,260 of 29,063 companies
33.3
score / 100
Value
29
Quality
37
FCF yld-2.1%
Earn yld-1.3%
EV/EBITDA·
ROE-14%
Gross mgn79%
Net mgn-36%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
100,000 shares@ HK$87.563548.2% of flowShareXHKGHKEX:DA20260615E00307
10 of 10 declarations
Acerca de Akeso, Inc.
Akeso, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades autoinmunes y cánceres. Se especializa en la investigación y comercialización de medicamentos basados en anticuerpos monoclonales.